RE:RE:RE:“Second mouse gets the cheese “Noteable wrote: With ONCY - being the second mouse and the only OV company that has a clinically proven and effective, systemically administered agent through intravenous (IV) injection able to address metastatic cancers.
Sept. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced it has completed a successful pre-Biologics License Application (pre-BLA) meeting with the U.S. Food and Drug Administration (FDA) that supports the Company’s plans to submit a BLA for RP1 (vusolimogene oderparepvec) for the treatment of anti-PD1 failed melanoma via the accelerated approval pathway in 2H 2024.
https://www.biospace.com/press-releases/replimune-announces-positive-pre-bla-meeting-with-fda-and-confirms-bla-submission-on-track-for-2h-2024
Any thoughts on upcoming fireside chats?